Online first
Original article
Published online: 2024-09-06
Increased parathyroid hormone concentration as a biomarker of atrial fibrillation in severe aortic stenosis
Pubmed: 39240914
Abstract
Not available
References
- Lindman BR, Clavel MA, Mathieu P, et al. Calcific aortic stenosis. Nat Rev Dis Primers. 2016; 2: 16006.
- Galli D, Manuguerra R, Monaco R, et al. Understanding the structural features of symptomatic calcific aortic valve stenosis: A broad-spectrum clinico-pathologic study in 236 consecutive surgical cases. Int J Cardiol. 2017; 228: 364–374.
- Olszowska M. Pathogenesis and pathophysiology of aortic valve stenosis in adults. Pol Arch Med Wewn. 2011; 121(11): 409–413.
- Conte M, Petraglia L, Campana P, et al. The role of inflammation and metabolic risk factors in the pathogenesis of calcific aortic valve stenosis. Aging Clin Exp Res. 2021; 33(7): 1765–1770.
- Pawade TA, Newby DE, Dweck MR. Calcification in aortic stenosis: The skeleton key. J Am Coll Cardiol. 2015; 66(5): 561–577.
- Matsuda S, Kato T, Morimoto T, et al. Causes of death in patients with severe aortic stenosis: An observational study. Sci Rep. 2017; 7(1): 14723–2511.
- Iung B, Algalarrondo V. Atrial fibrillation and aortic stenosis: Complex interactions between 2 diseases. JACC Cardiovasc Interv. 2020; 13(18): 2134–2136.
- Soulaidopoulos S, Xintarakou A, Vogiatzakis N, et al. Atrial fibrillation: An early marker of ventricular myocardial dysfunction. Kardiol Pol. 2024; 82(1): 86–89.
- Shekhar S, Saad A, Isogai T, et al. Impact of atrial fibrillation in aortic stenosis (from the United States readmissions database). Am J Cardiol. 2021; 140: 154–156.
- Gao P, Gao X, Xie B, et al. Aging and atrial fibrillation: A vicious circle. Int J Cardiol. 2024; 395: 131445.
- Hekimian G, Boutten A, Flamant M, et al. Progression of aortic valve stenosis is associated with bone remodelling and secondary hyperparathyroidism in elderly patients — the COFRASA study. Eur Heart J. 2013; 34(25): 1915–1922.
- Walker MD, Rundek T, Homma S, et al. Aortic valve calcification in mild primary hyperparathyroidism. J Clin Endocrinol Metab. 2012; 97(1): 132–137.
- Zheng MH, Li FX, Xu F, et al. The interplay between the renin-angiotensin-aldosterone system and parathyroid hormone. Front Endocrinol (Lausanne). 2020; 11: 539.
- Gruson D. PTH and cardiovascular risk. Ann Endocrinol (Paris). 2021; 82(3-4): 149–150.
- Olasińska-Wiśniewska A, Urbanowicz T, Grodecki K, et al. Monocyte-to-lymphocyte ratio correlates with parathyroid hormone concentration in patients with severe symptomatic aortic stenosis. Adv Med Sci. 2023; 68(2): 396–401.
- Vahanian A, Beyersdorf F, Praz F, et al. 2021 ESC/EACTS Guidelines for the management of valvular heart disease. Eur Heart J. 2021; 43(7): 561–632.
- McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021; 42(36): 3599–3726.
- Ozierański K, Kapłon-Cieślicka A, Peller M, et al. Clinical characteristics and predictors of one-year outcome of heart failure patients with atrial fibrillation compared to heart failure patients in sinus rhythm. Kardiol Pol. 2016; 74(3): 251–261.
- Balsam P, Tymińska A, Kapłon-Cieślicka A, et al. Predictors of one-year outcome in patients hospitalised for heart failure: results from the Polish part of the Heart Failure Pilot Survey of the European Society of Cardiology. Kardiol Pol. 2016; 74(1): 9–17.
- Kapłon-Cieślicka A, Vardas P, Grabowski M, et al. Tailoring guideline-directed medical therapy in heart failure with reduced ejection fraction: A practical guide. Kardiol Pol. 2023 [Epub ahead of print]; 81(9): 850–858.
- Majos-Karwacka E, Kowalik I, Kraska A, et al. Atrial fibrillation and elevated heart rate: Independent prognostic factors of right ventricular dysfunction in patients with heart failure with reduced ejection fraction. Kardiol Pol. 2022; 80(9): 938–939.
- A Reiffel J. The importance of atrial fibrillation's associated comorbidities as clinical presentation and outcome contributors. J Atr Fibrillation. 2021; 14(2): 20200517.
- Melenovský V, Osmančík P. Atrial fibrillation therapy and stroke prevention in hemodialysis patients. Kardiol Pol. 2023; 81(12): 1193–1204.
- Lind A, Azizy O, Lortz J, et al. Percutaneous left atrial appendage closure for stroke prevention in patients with chronic renal disease. Arch Med Sci. 2023; 19(2): 331–336.
- Gadde S, Kalluru R, Cherukuri SP, et al. Atrial fibrillation in chronic kidney disease: An overview. Cureus. 2022; 14(8): e27753.
- Ahn HJ, Han KD, Choi EK, et al. Cumulative burden of metabolic syndrome and its components on the risk of atrial fibrillation: A nationwide population-based study. Cardiovasc Diabetol. 2021; 20(1): 20.
- Ahmad M, Reddy S, Barkhane Z, et al. Hyperthyroidism and the risk of cardiac arrhythmias: A narrative review. Cureus. 2022; 14(4): e24378.
- Bekiaridou A, Kartas A, Moysidis DV, et al. The bidirectional relationship of thyroid disease and atrial fibrillation: Established knowledge and future considerations. Rev Endocr Metab Disord. 2022; 23(3): 621–630.
- Lincoff AM, Bhasin S, Flevaris P, et al. Cardiovascular safety of testosterone-replacement therapy. N Engl J Med. 2023; 389(2): 107–117.
- Murat K, Oguzhan Y, Hakan G, et al. The relationship between atrial fibrillation and parathyroid hormone in heart failure outpatients. Kardiologiia. 2023; 63(9): 51–55.
- Altay H, Zorlu A, Binici S, et al. Relation of serum parathyroid hormone level to severity of heart failure. Am J Cardiol. 2012; 109(2): 252–256.
- Kobayashi T, Kitahara H, Kato K, et al. Impact of parathyroid hormone level on intracoronary calcification and short- and long-term outcomes in dialysis patients undergoing percutaneous coronary intervention. Circ J. 2023; 87(2): 247–255.
- Zia AA, Kamalov G, Newman KP, et al. From aldosteronism to oxidative stress: the role of excessive intracellular calcium accumulation. Hypertens Res. 2010; 33(11): 1091–1101.
- Kamalov G, Ahokas RA, Zhao W, et al. Temporal responses to intrinsically coupled calcium and zinc dyshomeostasis in cardiac myocytes and mitochondria during aldosteronism. Am J Physiol Heart Circ Physiol. 2010; 298(2): H385–H394.
- Tomaschitz A, Ritz E, Pieske B, et al. Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease. Metabolism. 2014; 63(1): 20–31.
- Milicic Stanic B, Ilincic B, Zeravica R, et al. The importance of correlation between aldosterone and parathyroid hormone in patients with primary hyperparathyroidism. Int J Endocrinol. 2022; 2022: 3804899.
- Brown NJ. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis. Nat Rev Nephrol. 2013; 9(8): 459–469.
- Olasinska-Wisniewska A, Mularek-Kubzdela T, Grajek S, et al. Impact of atrial remodeling on heart rhythm after radiofrequency ablation and mitral valve operations. Ann Thorac Surg. 2012; 93(5): 1449–1455.
- Saljic A, Friederike Fenner M, Winters J, et al. Increased fibroblast accumulation in the equine heart following persistent atrial fibrillation. Int J Cardiol Heart Vasc. 2021; 35: 100842.
- Ling LH, Kistler PM, Ellims AH, et al. Diffuse ventricular fibrosis in atrial fibrillation: noninvasive evaluation and relationships with aging and systolic dysfunction. J Am Coll Cardiol. 2012; 60(23): 2402–2408.
- Burton DW, Brandt DW, Deftos LJ. Parathyroid hormone-related protein in the cardiovascular system. Endocrinology. 1994; 135(1): 253–261.
- Deftos LJ, Burton DW, Brandt DW. Parathyroid hormone-like protein is a secretory product of atrial myocytes. J Clin Invest. 1993; 92(2): 727–735.
- Wiśniewska J, Drohomirecka A, Wiligórska N, et al. The elevated serum parathyroid hormone level is associated with the occurrence of atrial fibrillation in patients with advanced heart failure. Kardiol Pol. 2020; 78(12): 1274–1277.
- Belen E, Aykan AC, Kalaycioglu E, et al. Low-level vitamin D is associated with atrial fibrillation in patients with chronic heart failure. Adv Clin Exp Med. 2016; 25(1): 51–57.
- Arase H, Yamada S, Tanaka S, et al. Association between plasma intact parathyroid hormone levels and the prevalence of atrial fibrillation in patients with chronic kidney disease — the Fukuoka kidney disease registry study. Circ J. 2020; 84(7): 1105–1111.
- Trevisan C, Piovesan F, Lucato P, et al. Parathormone, vitamin D and the risk of atrial fibrillation in older adults: A prospective study. Nutr Metab Cardiovasc Dis. 2019; 29(9): 939–945.
- Rienstra M, Lubitz SA, Zhang ML, et al. Elevation of parathyroid hormone levels in atrial fibrillation. J Am Coll Cardiol. 2011; 57(25): 2542–2543.
- Lee CY, Tsai CM, Chiang KC, et al. Prognostic value of left ventricular and left atrial strain imaging in moderate to severe aortic stenosis: Insights from an Asian population. Int J Cardiol. 2024; 407: 132103.
- Hara M, Liu YM, Zhen L, et al. Positive chronotropic actions of parathyroid hormone and parathyroid hormone-related peptide are associated with increases in the current, I(f), and the slope of the pacemaker potential. Circulation. 1997; 96(10): 3704–3709.
- Hof I, Arbab-Zadeh A, Scherr D, et al. Correlation of left atrial diameter by echocardiography and left atrial volume by computed tomography. J Cardiovasc Electrophysiol. 2009; 20(2): 159–163.
